Free Trial

Eliem Therapeutics Q1 2024 Earnings Report

Eliem Therapeutics logo
$2.02 -0.32 (-13.46%)
(As of 12/18/2024 ET)

Eliem Therapeutics EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eliem Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eliem Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 

Eliem Therapeutics Earnings Headlines

Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
See More Eliem Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eliem Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eliem Therapeutics and other key companies, straight to your email.

About Eliem Therapeutics

Eliem Therapeutics (NASDAQ:ELYM), a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

View Eliem Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings